Free Trial
NYSE:EBS

Emergent Biosolutions (EBS) Stock Price, News & Analysis

Emergent Biosolutions logo
$6.63 -0.36 (-5.15%)
Closing price 03:59 PM Eastern
Extended Trading
$6.64 +0.01 (+0.23%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Emergent Biosolutions Stock (NYSE:EBS)

Key Stats

Today's Range
$6.59
$6.94
50-Day Range
$4.74
$7.08
52-Week Range
$4.02
$15.10
Volume
1.00 million shs
Average Volume
1.73 million shs
Market Capitalization
$359.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.33
Consensus Rating
Buy

Company Overview

Emergent Biosolutions Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
86th Percentile Overall Score

EBS MarketRank™: 

Emergent Biosolutions scored higher than 86% of companies evaluated by MarketBeat, and ranked 140th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Emergent Biosolutions has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Emergent Biosolutions has received no research coverage in the past 90 days.

  • Read more about Emergent Biosolutions' stock forecast and price target.
  • Earnings Growth

    Earnings for Emergent Biosolutions are expected to grow in the coming year, from ($0.63) to $2.07 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Emergent Biosolutions is -2.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Emergent Biosolutions is -2.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Emergent Biosolutions has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Emergent Biosolutions' valuation and earnings.
  • Percentage of Shares Shorted

    15.39% of the float of Emergent Biosolutions has been sold short.
  • Short Interest Ratio / Days to Cover

    Emergent Biosolutions has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in Emergent Biosolutions has recently increased by 2.04%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Emergent Biosolutions does not currently pay a dividend.

  • Dividend Growth

    Emergent Biosolutions does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.39% of the float of Emergent Biosolutions has been sold short.
  • Short Interest Ratio / Days to Cover

    Emergent Biosolutions has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in Emergent Biosolutions has recently increased by 2.04%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Emergent Biosolutions has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Emergent Biosolutions this week, compared to 5 articles on an average week.
  • Search Interest

    Only 1 people have searched for EBS on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Emergent Biosolutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $49,417.00 in company stock.

  • Percentage Held by Insiders

    Only 3.20% of the stock of Emergent Biosolutions is held by insiders.

  • Percentage Held by Institutions

    78.40% of the stock of Emergent Biosolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Emergent Biosolutions' insider trading history.
Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent Biosolutions and its competitors with MarketBeat's FREE daily newsletter.

EBS Stock News Headlines

Emergent BioSolutions Inc. (EBS) - Yahoo Finance
Banks aren’t ready for this altcoin—are you?
I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.
See More Headlines

EBS Stock Analysis - Frequently Asked Questions

Emergent Biosolutions' stock was trading at $9.56 at the beginning of the year. Since then, EBS shares have decreased by 30.6% and is now trading at $6.63.

Emergent Biosolutions Inc. (NYSE:EBS) issued its quarterly earnings data on Wednesday, May, 7th. The biopharmaceutical company reported $0.71 earnings per share for the quarter, beating analysts' consensus estimates of $0.49 by $0.22. The biopharmaceutical company earned $222.20 million during the quarter, compared to analyst estimates of $218.50 million. Emergent Biosolutions had a negative trailing twelve-month return on equity of 0.52% and a negative net margin of 13.63%.
Read the conference call transcript
.

Emergent Biosolutions' board approved a stock buyback program on Monday, March 31st 2025, which permits the company to buy back $50,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 19% of its stock through open market purchases. Stock buyback programs are often a sign that the company's management believes its stock is undervalued.

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Emergent Biosolutions investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alibaba Group (BABA) and Moderna (MRNA).

Company Calendar

Last Earnings
5/07/2025
Today
7/07/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NYSE:EBS
Employees
2,420
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.33
High Stock Price Target
$16.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+113.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$190.60 million
Pretax Margin
-6.45%

Debt

Sales & Book Value

Annual Sales
$1.04 billion
Cash Flow
$1.85 per share
Price / Cash Flow
3.64
Book Value
$8.91 per share
Price / Book
0.75

Miscellaneous

Free Float
52,541,000
Market Cap
$365.03 million
Optionable
Optionable
Beta
2.09
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NYSE:EBS) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners